9 or <0
H&E and ORO staining and hepatic TG measurement revealed that lower-dose tamoxifen decreased hepatic steatosis and hepatic TG and 5 mg/kg tamoxifen
on potential tamoxifen‐related liver steatosis have been conducted in Caucasian patients so far
Tamoxifen has been used for a long time as a hormonal treatment in breast cancer
Tamoxifen is an important anti-estrogen agent used for the treatment of hormone receptor-positive breast cancer and it may induce reversible hepatic steatosis
Tamoxifen is a potent antagonist of estrogen and evidently improves the prognosis of patients with estrogen receptor-positive breast cancer
Among these, hepatic steatosis and steatohepatitis are the most commonly seen
Drug-induced steatosis/steatohepatitis is in fact an exclusion criterion for NAFLD, but patients with NAFLD and T2DM/obesity are often pluri-medicated, and there
Several studies have
Tamoxifen is an antiestrogenic agent used widely in the treatment and chemoprevention of breast cancer
However, when Mttp flox mice were fed an MCD for 5 weeks and then administered tamoxifen to induce Mttp-IKO, hepatic TG was reduced, but inflammation and fibrosis were increased after 10 days of reversal along with adaptive changes in hepatic lipogenic mRNAs
Meanwhile, there is no drug to prevent and treat it
A Here, we show that tamoxifen treatment for 5 days decreases fat mass for as long as 18 weeks in mice fed HFD
The fatty acid synthase protein was normally expressed at 12 days but was decreased by 52% at 28 days
The patients underwent postoperative annual abdominal CT, both with and without contrast
Among these drugs there are some anti-tumoral molecules, such as methotrexate, 5-fluorouracil, irinotecan, tamoxifen and l-asparaginase
Although tamoxifen can trigger steatohepatitis, the mechanism of steatosis is unclear
Steatosis of hepatocytes was determined after Oil Red O staining and measurement of
0 vs 81 ± 0
Recently we reported the impairment of fatty acid β-oxidation and the enhancing fatty infiltration to hepatocytes in aromatase deficiency (ArKO) mice as Short-term tamoxifen administration largely improved hepatic steatosis and insulin resistance, however, the phenotypes manifesting inflammation and fibrosis remained unchanged in abovementioned In another study of 105 breast cancer patients treated with tamoxifen, hepatic steatosis was recognized in the majority of patients within the first 2 years of receiving adjuvant tamoxifen, with only half of the patients having increased transaminase levels
As such, there was a reduction of combined cyst volume
Human multilineage 3D spheroids as a model of liver steatosis and fibrosis